Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could

The article highlights three biotech names with credible near-term doubling potential: ADMA Biologics, EyePoint Pharmaceuticals, and Viking Therapeutics. ADMA is already profitable, with Q1 net income of $407 million, while EyePoint and Viking could benefit from upcoming late-stage data readouts and large addressable markets, including a combined $15 billion wet AMD/DME opportunity and a growing GLP-1 obesity market. Wall Street is notably bullish, with consensus price targets implying 140% upside for ADMA, 165% for EyePoint, and 146% for Viking.

Analysis

The real common denominator here is not “biotech upside” but duration mismatch: each name has a near-term binary catalyst that can reprice the stock far faster than the underlying business can be modeled. ADMA is the only one with existing earnings power, which matters because it converts clinical-style optionality into a de-risked rerating story; if management can keep yield improvements flowing through to margins, the market can justify a higher terminal multiple well before revenue growth alone would. By contrast, EYPT and VKTX are effectively event-driven call options with no cash-flow floor, so the market is paying for probability-weighted data readouts rather than fundamentals.

Competitive dynamics are more interesting than the headline targets suggest. If Duravyu works, the second-order winner is not just EYPT but the entire retinal-treatment ecosystem: payers, retina clinics, and procedure-heavy practices that benefit from fewer injections and better throughput. That also creates direct displacement pressure on incumbent anti-VEGF franchises, but the larger risk is that a differentiated convenience profile still fails to overcome entrenched reimbursement and physician habit, which would compress the stock quickly after data if efficacy is merely “good” instead of clearly superior. In GLP-1, VKTX’s upside is greatest if investors decide supply-chain constraints and tolerability remain the real bottlenecks; otherwise the market will keep assigning it a discount to the incumbents because commercialization risk, not molecule quality, is the gating factor.

The consensus seems to be underpricing financing and execution asymmetry. For both EYPT and VKTX, the next 6-12 months matter far more than the next 2-3 years: positive data likely triggers a sharp multiple expansion, while mixed data forces capital raises at lower prices and destroys the “double” setup. ADMA is the cleaner long because it can compound without binary dilution risk, but it is also the least convex; the market may be underestimating how much of the upside is already de-risked, so upside could be slower than the target implies.

Key Decisions for Investors

• Long ADMA into the next 1-2 quarters: best risk-adjusted setup because operating leverage can compound without binary trial risk; target a rerating toward consensus upside, trim if the market begins to price in perfection rather than growth.
• Trade EYPT as a catalyst long only into data: consider a call spread into the readout window to express asymmetric upside while limiting downside if efficacy is merely adequate; avoid holding full size through ambiguous results.
• For VKTX, prefer a calendarized options structure over outright equity: long-dated calls or a call spread captures Phase 3 optionality while capping dilution/financing risk if the market de-risks slower than expected.
• Pair trade idea: long ADMA / short a basket of pre-revenue biotech names with near-term binary events; this isolates the profitable compounding story versus the financing-dependent duration trade.
• If EYPT or VKTX gaps up on positive headlines, take partial profits into the first 24-48 hours: these names are likely to overshoot on headline-driven momentum, but sustaining gains will require follow-through on reimbursement and commercialization evidence.